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Hyperglycemia Has a Greater
Impact on Left Ventricle Function
in South Asians Than in Europeans
OBJECTIVE
Diabetes is associated with left ventricular (LV) diastolic and systolic dysfunction.
South Asiansmay be at particular risk of developing LV dysfunction owing to a high
prevalence of diabetes. We investigated the role of diabetes and hyperglycemia in
LV dysfunction in a community-based cohort of older South Asians and white
Europeans.
RESEARCH DESIGN AND METHODS
Conventional and Doppler echocardiography was performed in 999 participants
(542 Europeans and 457 South Asians aged 58–86 years) in a population-based
study. Anthropometry, fasting bloods, coronary artery calciﬁcation scoring, blood
pressure, and renal function were measured.
RESULTS
Diabetes and hyperglycemia across the spectrum of HbA1c had a greater adverse
effect on LV function in South Asians than Europeans (N-terminal-probrain na-
triuretic peptide b 6 SE 0.09 6 0.04, P = 0.01, vs. 20.04 6 0.05, P = 0.4, P for
HbA1c/ethnicity interaction 0.02), diastolic function (E/e9 0.696 0.12, P < 0.0001,
vs. 0.09 6 0.2, P = 0.6, P for interaction 0.005), and systolic function (s9 20.11 6
0.06, P = 0.04, vs. 0.14 6 0.09, P = 0.1, P for interaction 0.2). Multivariable ad-
justment for hypertension, microvascular disease, LV mass, coronary disease, and
dyslipidemia only partially accounted for the ethnic differences. Adverse LV
function in diabetic South Asians could not be accounted for by poorer glycemic
control or longer diabetes duration.
CONCLUSIONS
Diabetes and hyperglycemia have a greater adverse effect on LV function in South
Asians than Europeans, incompletely explained by adverse risk factors. South
Asians may require earlier and more aggressive treatment of their cardiometa-
bolic risk factors to reduce risks of LV dysfunction.
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Diabetes is a major risk factor for
cardiovascular disease (CVD) and heart
failure (1), which is of increasing
importance as a consequence of
increasing diabetes prevalence and
aging populations. However the
existence of a distinct diabetes-related
cardiomyopathy, speciﬁcally as a
consequence of hyperglycemia, is
controversial (2–4). Understanding the
underlying mechanisms driving the
association between diabetes and left
ventricular (LV) function is greatly
assisted by studying ethnic minority
groups where risk factor clustering
markedly differs.
South Asians across the world have a
substantially elevated risk of diabetes.
In comparison with European-origin
populations, diabetes prevalence is
fourfold greater; by the age of 80 years,
one in two South Asians will have
developed diabetes compared with only
one in ﬁve Europeans (5). We have
reported that diabetes increases the risk
of stroke and ischemic heart disease to a
greater extent in South Asians than
Europeans (6) for reasons that are
unclear. It is unknown whether diabetes
also exerts a more adverse impact of LV
function and risk of heart failure in
South Asians.
The comparative risk of heart failure has
not beenmeasured directly but could be
as much as ﬁvefold higher in South
Asians (7), and there is growing
evidence that survival, severity, and
etiology of heart failure also differ by
ethnicity (8). Both LV systolic
dysfunction (LVSD) and diastolic
dysfunction (LVDD) are independent
risk factors for development of heart
failure and cardiac death (9,10). Heart
failure in middle-age is rare but emerges
with older age and with population
aging. Studying risk factor associations
with subclinical disease may shed light
on underlying risks andmechanisms and
avoid the problem of medication for
heart failure altering the nature of their
outcomes.
Ethnic differences in prevalence and
severity of LV dysfunction have been
reported (8,11–13); however, these
reports are from selected populations
with established disease or with all
morbidities excluded and therefore
cannot fully explore the role of diabetes
and hyperglycemia in accounting for
ethnic differences in risk (14–17). Given
the elevated rates of diabetes and
adverse CVD risk factors in South Asians,
previous studies excluding individuals
with known CVD or risk factors (13) may
have therefore resulted in biased
comparisons.
We therefore aimed to test the
hypotheses that diabetes and the
spectrum of hyperglycemia would be
associated with measures of LV
dysfunction and that these relationships
would differ by ethnicity. We also sought
to establish whether established risk
factors could account for any ethnic
differences observed in these associations.
RESEARCH DESIGN AND METHODS
Study Population
A population-based sample of 1,206
men and women of white European and
South Asian ethnicity was recruited
from the Southall and Brent REvisited
(SABRE) cohort. SABRE recruited
between 1988 and 1991 between the
ages of 40 and 69 years from West
London primary care registers (18).
Random selection of participants was
made from 5-year age- and sex-
stratiﬁed primary care physician lists
and workplaces in the London districts
of Southall and Brent. This article
presents a cross-sectional analysis
derived from the 20-year follow-up
data. All surviving participants were
invited to participate in the follow-up
study; the only exclusion criterion was if
patients were not able to give informed
consent. At the follow-up clinic in 2008–
2011, participants were aged 59–86
years. Ethics committee approval was
obtained, and all participants gave
written informed consent. Ethnicity was
assigned by clinic staff and conﬁrmed by
participants. All South Asians were ﬁrst-
generation migrants from the Indian
subcontinent, and the majority were of
Punjabi origin. Participants were fasted for
12 h and refrained frommedication on the
morning of their visit. They completed a
questionnaire detailing health behaviors,
morbidity, and medications.
Clinic Data and Blood/Urine
Measurements
Height, weight, waist and hip
circumference, and blood pressure were
measured under standardized
conditions (18), and the waist-to-hip
circumference ratio (WHR) was
calculated. Fasting samples were
analyzed for blood glucose, glycosylated
hemoglobin (HbA1c), insulin, triglycerides,
and total and HDL cholesterol,
and the total cholesterol–to–HDL
cholesterol ratio was calculated. Serum
N-terminal-probrain natriuretic peptide
(NT-proBNP) was measured using an
Elecsys 2010 electrochemiluminescence
analyzer (Roche Diagnostics, Burgess
Hill, U.K.) calibrated using the
manufacturer’s reagents. A spot early-
morning urine sample was measured
for albumin and creatinine.
Microalbuminuria was deﬁned as an
albumin-to-creatinine ratio .2.5
mg/mol for men and .3.5 mg/mol for
women. Established diabetes was
diagnosed as patient or GP reported
and deﬁned according to the 1999
World Health Organization guidelines
(19). Those without known diabetes
underwent an oral glucose tolerance test.
Diabetes duration was established by
questionnaire. Hypertension was deﬁned
as physician-diagnosed hypertension or
participant-reported hypertension in
people receiving blood pressure–lowering
medication.
Two-Dimensional and Conventional
and Tissue Doppler Echocardiography
Transthoracic two-dimensional (2D) and
Doppler echocardiography was
performed as previously described (20)
to assess both systolic and diastolic
function on 602 Europeans (88%) and
480 South Asians (92%). Left atrial
diameter was measured and indexed to
height2.7 (LADi). Full Doppler
echocardiography could not be
performed on 84 individuals with poor
acoustic windows (8%) or 40 individuals
in atrial ﬁbrillation (4%). Transmitral
ﬂow velocity during the early ﬁlling
phase (E), its deceleration time (DT) (a
measure of LV relaxation), and the late
ﬁlling phase (A) was acquired by pulsed
Doppler and averaged from three
consecutive cycles. Tissue Doppler
echocardiography was performed on
the lateral and septal LV wall. Peak
velocities during systole (s9) early
diastole (e9) and late diastole (a9) were
averaged from three consecutive cycles.
The s9, e9, and a9 wave velocities taken
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from the lateral and septal walls were
averaged. Intra- and interobserver
reproducibility of echocardiographic
measures was assessed by separate scans
(on different days) performed in 10
participants selected at random. Intra-
and interobserver reproducibility was
excellent for all key measures (intraclass
correlation coefﬁcients.0.80).
Calculated Variables
Doppler Variables
The ratio of the transmitral early and
late ﬁlling phases (E:A) was calculated
as a measure of diastolic function. The
ratio of early ﬁlling and early myocardial
velocity (E/e9) was calculated as a
noninvasive index of LV ﬁlling pressure.
2D Echocardiography Variables
LV mass was calculated as previously
described (21).
LV mass ¼ 0:83

1:043
ðIVSðdÞ þ LVIDðdÞ
þ PWTðdÞÞ3- LVIDðdÞ3þ0:6
LV mass and left atrial diameter were
indexed to height2.7 (LV mass index
[LVMI]) (22). Ejection fraction (EF) was
calculated as a measure of systolic
function.
EF¼ ðstroke volume
=end-diastolic volume Þ3100
LV Dysfunction
To establish the burden of prevalent
disease for cross-study comparison,
systolic dysfunction was deﬁned as EF
,50%. Diastolic dysfunction was
assessed on the basis of the tissue
Doppler mitral annular velocities and
the Doppler measures of mitral inﬂow.
Cutoffs conformed to guidelines for
diastolic function (23).
Key Measures of Function
Key measures were selected a priori and
analyzed as continuous variables. With
use of newer echocardiographic
measures, which are more precise and
less prone to pseudonormalization, our
key comparator was s9 for longitudinal
systolic function and E/e9 for diastolic
function. NT-proBNP levels indicated LV
global dysfunction (24).
Coronary Artery Calciﬁcation Score and
Coronary Heart Disease
Coronary artery calciﬁcation score
(CACS) was acquired using a Philips 64
slice CT scanner as previously described
(25). Scans were read by an experienced
radiographer blinded to participant
ethnicity and other characteristics. The
intraclass correlation coefﬁcient was
.0.9. CACS were combined with
coronary heart disease (CHD) information
to create a combined clinical/subclinical
CHD variable, labeled CACS/CHD.
Categories were based on previously
accepted cut points. Category 1 included
individuals with minimal CACS (,10
arbitrary units [AU]) and no CHD,
category 2 included individuals with
moderate CACS (10–400 AU) and no CHD,
and category 3 included individuals with
severe CACS (.400 AU) or prevalent
CHD, deﬁned as a coronary event or
revascularization identiﬁed by medical
record review and adjudicated by an
independent committee (6).
Data Analysis
Statistical analyses were performed
using Stata 12.0. Of the 1,206 (684
Europeans and 522 South Asians)
attending clinic, 1,082 (602 Europeans
and 480 South Asians) underwent 2D
and Doppler echocardiography. Of
these, 999 (542 Europeans and 457
Table 1—Participant demographics and LV functional measures
European South Asian P
n 542 457
Male, n (%) 419 (77) 387 (85) 0.003
Age (years) 69.8 6 6.3 68.9 6 6.1 0.03
BMI (kg/m2) 27.6 6 4.6 26.2 6 3.7 ,0.0001
WHR 0.97 6 0.07 1.00 6 0.07 ,0.0001
CHD/CACS .400 AU 76 (14) 132 (29) ,0.0001
Microalbuminuria, n (%) 76 (14) 100 (22) 0.001
Hypertension, n (%) 295 (54) 341 (75) ,0.0001
SBP (mmHg) 138 6 17 142 6 18 0.001
DBP (mmHg 77 6 10 76 6 10 0.2
HR 68 6 12 67 6 13 0.09
NGT, n (%) 310 (57) 179 (40) ,0.0001
IGT/IFG, n (%) 133 (25) 89 (19) ,0.0001
Diabetes, n (%) 99 (18) 189 (41) ,0.0001
Diabetes duration (years) 4.5 (0, 9) 9.0 (2, 19) 0.001
Fasting glucose (mmol/L) 5.1 (4.8, 5.6) 5.3 (4.8, 6.1) 0.0001
HbA1c (%) 5.9 (5.6, 6.2) 6.2 (5.9, 6.9) ,0.0001
HbA1c (mmol/mol) 41 (38, 44) 44 (41, 52) ,0.0001
Insulin (pmol/L) 8.4 (5.4, 13) 9.7 (6.2, 15) 0.01
Fasting triglycerides (mmol/L) 1.14 (0.9, 1.5) 1.21 (0.9, 1.7) 0.02
Cholesterol:HDL (mmol/L) 3.5 (2.9, 4.2) 3.4 (2.8, 4.2) 0.6
LVMI-2D (g/m2.7) 43.7 6 12 42.0 6 11 0.02
LVSD (%) 118 (22) 93 (20) 0.6
EF (%) 61 6 10 62 6 9 0.4
Peak s9 (cm/s) 7.80 6 1.4 7.46 6 1.4 ,0.0001
LVDD, n (%) 511 (94) 422 (92) 0.2
E:A 0.84 6 0.2 0.89 6 0.3 0.005
DT (ms) 245 6 51 236 6 50 0.006
Peak e9 (cm/s) 7.21 6 1.8 7.20 6 1.8 0.9
E/e9 8.75 6 2.8 9.85 6 3.1 ,0.0001
LADi (cm/ m2.7) 0.96 6 0.2 0.99 6 0.2 0.0007
NT-proBNP (pg/mL) 134 (123–149) 150 (136–164) 0.2
NT-proBNP adjusted for LV mass 131 (118–144) 156 (141–170) 0.02
Data are mean 6 SD, median (interquartile range) for skewed data, n (%) for categorical data,
and mean (95% CI) for NT-proBNP. DBP, diastolic blood pressure; HR heart rate; IGT impaired
glucose tolerance; IFG, impaired fasting glucose; NGT, normal glucose tolerance; peak e9, mitral
annular early peak diastolic velocity; peak s9, mitral annular peak systolic velocity; SBP, brachial
systolic blood pressure.
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South Asians) had full covariate data.
Participant characteristics are reported
as mean 6 SD, median (interquartile
range) for skewed data, and n (%) for
categorical data. Ethnic group
comparisons were made using ANOVA
or covariance (ANCOVA). Covariates
(age, sex, heart rate, hypertension, ratio
of total cholesterol to HDL, WHR,
microalbuminuria, clinical/subclinical
CHD, and LV mass) were chosen a priori
based on their known inﬂuence on LV
function (26). For related variables (e.g.,
BMI and WHR), the single variable that
most attenuated the ethnic difference
was retained in the ﬁnal model.
Signiﬁcance was assigned at P , 0.05.
We previously showed important
ethnicity 3 diabetes interactions for
clinical end points (CVD events and
stroke) (6) and hypothesized that these
would be present for subclinical disease.
Ethnic differences in systolic and diastolic
functionwere similar inmen andwomen,
so sexes were combined for analysis.
RESULTS
Participant Characteristics
Mean agewas ~69 years (Table 1). South
Asians had a greater prevalence and
duration of type 2 diabetes (P ,
0.0001), and more frequent clinical plus
subclinical CHD (P , 0.0001),
microalbuminuria (P = 0.001), and
hypertension (P , 0.0001) than
Europeans. They also had more adverse
lipid proﬁles (triglycerides, P = 0.02),
were hyperinsulinemic (P = 0.01), and
were more centrally obese (WHR, P ,
0.0001).
LV Measures
NT-proBNP was nonsigniﬁcantly higher
in South Asians than Europeans (P = 0.2).
On adjustment for LV mass, this ethnic
difference increased and became
statistically signiﬁcant (P = 0.02) (Table 1).
South Asians had reduced LVMI
compared with Europeans (P = 0.02).
While there was no ethnic difference in
prevalence of systolic dysfunction
(LVSD, P = 0.6) as assessed by EF, peak s9
was signiﬁcantly lower in South Asians
than Europeans (P , 0.0001) (Table 1).
Diastolic dysfunction, largely mild, was
common in both ethnic groups (P = 0.2)
(Table 1). E:A and E/e9were signiﬁcantly
higher in South Asians than Europeans
(E:A, P = 0.005; E/e9, P, 0.0001). DTwas
signiﬁcantly reduced in South Asians (P =
0.006) and LADi was signiﬁcantly larger
(P = 0.0007) (Table 1).
LV Function and HbA1c Within Ethnic
Groups
Statistically signiﬁcant interactions
between glycemic status and ethnic-
ity on key measures of LV function were
observed, and therefore associations
between glycemia and function were
analyzed separately by ethnicity.
Glycated hemoglobin was not related to
any measure of LV function in
Europeans (NT-proBNP b [SE] 20.04
[0.05], P = 0.4; E/e9 0.09 [0.2], P = 0.6;
and peak s9 0.14 [0.09], P = 0.1) (Table 2)
but was strongly and adversely
associated with functional measures in
South Asians (NT-proBNP 0.09 [0.04], P =
0.01; E/e9 0.69 [0.12], P , 0.0001; and
peak s9 20.11 (0.06), P = 0.04). After
further adjustment for key cardiometabolic
risk factors (heart rate, hypertension,
total cholesterol–to–HDL ratio, WHR,
microalbuminuria, CHD/CACS, and LV
mass), the signiﬁcant association between
HbA1c and E/e9 in South Asians remained
(0.52 [0.12], P, 0.0001); however, the
associations with peak s9 (20.06 [0.05],
P = 0.3) and NT-proBNP (0.02 [0.04], P =
0.5) were attenuated. Full regression
results are presented in Supplementary
Table 1 for Europeans and Supplementary
Table 2 for South Asians.
Exploration of Interactions Between
Ethnic Group and HbA1c/Glucose
Tolerance Categories
For most measures of LV function,
worsening glycemic status had a more
adverse effect on LV function in South
Asians than Europeans, which was
statistically signiﬁcant when tested as
an interaction. Across glucose tolerance
categories, interaction tests were b (SE)
0.14 (0.06), P = 0.02, for NT-proBNP;
0.46 (0.22), P = 0.03, for E/e9; and20.05
(0.10), P = 0.6, for s9 (Fig. 1A–C).
Multivariable adjustment for age, sex,
heart rate, hypertension, total
cholesterol–to–HDL ratio, WHR,
microalbuminuria, CHD/CACS, and LV
mass did not abolish the statistically
signiﬁcant interaction for NT-proBNP (b
[SE] 0.14 [0.06], P = 0.02) but did slightly
attenuate the E/e9 interaction (0.39
[0.21], P = 0.06).
Similarly, HbA1c also had a signiﬁcantly
greater adverse impact on all three
measures of LV function in South Asians
than Europeans (NT-proBNP interaction
b [SE] 0.14 [0.06], P = 0.02; E/e9 0.58
[0.21], P = 0.005; and s920.24 [0.10], P =
0.02) (Fig. 1D–F). These interactions
remained statistically signiﬁcant on
multivariate adjustment (NT-proBNP
0.14 [0.06], P = 0.01; E/e9 0.62 [0.20], P =
0.002; and s920.21 [0.10], P = 0.03). Full
interaction details are presented in
Supplementary Table 3.
The greater adverse effect of
hyperglycemia on LV function in South
Asians could be due to their longer
duration of exposure. Diabetes duration
was almost twofold greater in South
Asians (Table 1). In people with diabetes,
diabetes duration associated signiﬁcantly
with higher NT-proBNP (b [SE] 4.4 [1.2],
P , 0.0001) and E/e9 (0.08 [0.2], P =
0.001) and with slightly poorer s9
(20.01 [0.01] cm/s, P = 0.3). These
associations were independent of the
Table 2—Association between measures of LV function and HbA1c stratiﬁed
by ethnicity
European (n = 542) South Asian (n = 457)
b (SE) P b (SE) P
NT-proBNP (pg/mL)
Model 1 20.04 (0.05) 0.4 0.09 (0.04) 0.01
Model 2 20.08 (0.05) 0.08 0.02 (0.04) 0.5
E/e9
Model 1 0.09 (0.2) 0.6 0.69 (0.12) ,0.0001
Model 2 20.13 (0.17) 0.4 0.52 (0.12) ,0.0001
Peak s9 (cm/s)
Model 1 0.14 (0.09) 0.1 20.11 (0.06) 0.04
Model 2 0.16 (0.09) 0.06 20.06 (0.05) 0.3
Data are b (SE). Model 1, adjusted for age and sex; model 2, adjusted for age, sex, heart rate,
hypertension, ratio of total cholesterol to HDL,WHR, microalbuminuria, clinical/subclinical CHD,
and LV mass.
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effect of HbA1c for NT-proBNP (P = 0.001)
and E/e9 (P = 0.004). However, when we
compared NT-proBNP, E/e9, and s9 by
ethnicity in those with established
diabetes (where diabetes duration can
be estimated), we found that
adjustment for diabetes duration, and
for HbA1c, could account for little of the
ethnic difference in observed function
(Table 3 and Supplementary Table 4). In
those with established diabetes, we also
found that the interactions between
glycemic status and ethnicity on key
measures of LV function (NT-proBNP
0.24, P = 0.05; E/e9 0.59, P = 0.2; and s9
20.38, P = 0.04) remained after further
adjustment for diabetes duration (NT-
proBNP 0.26, P = 0.04; E/e9 0.77, P = 0.1;
and s9 20.45, P = 0.02).
CONCLUSIONS
Diabetes and hyperglycemia across the
spectrum of HbA1c into the normal
range have a far more adverse effect on
global (NT-proBNP), diastolic (E/e9), and
systolic (s9) ventricular function in South
Asians than Europeans; hyperglycemia
appeared to have little relationship
with LV function in Europeans. The
association between worse glycemic
status and LV function in South Asians
could largely (particularly for systolic
and global function) be accounted for
by concomitant cardiometabolic risk
factors such as hypertension, presence
of clinical and subclinical CHD,
microalbuminuria, dyslipidemia, and
central obesity. Previous studies have
shown that systolic or diastolic LV
dysfunction are relatively common in
older people (10) and independently
predict heart failure (9,27) and total
mortality (10,28) in European general
population samples; e.g., mild diastolic
dysfunction was associated with a
more than eightfold increase in hazard
of all-cause mortality in people aged 45
years or older (10). To our knowledge,
no previous study has investigated
ethnic differences in the relationship
between glycemic status and LV
function, but our ﬁndings could help to
explain the increased risk of heart
failure and cardiovascular events in
South Asians.
Our ﬁnding of poorer longitudinal
systolic and diastolic function in South
Asians compared with Europeans is in
accordance with a smaller previous
study, although this latter was restricted
to individuals with no abnormal risk
factors, disease, or medication (28) and
therefore could not explore the role of
glycemic status on LV function.
In Europeans, there was little
association between glycated
hemoglobin and LV dysfunction and
only a modest decline in people with
diabetes. Previous studies in European
origin populations are conﬂicting, with
some showing marked functional LV
impairment when comparing people
with and without diabetes (29) and
across the glycemic spectrum (30),
whereas others show no differences
between people with and without
diabetes (31,32) and mixed associations
across the glycemic spectrum (13). A
detailed study of the effect of diabetes
on LV function noted that while
longitudinal systolic function was
impaired, radial function was increased
compared with those without diabetes
(33). These conﬂicting ﬁndings in part
could be explained by choice of study
population, e.g., clearer associations are
Figure 1—A–C: Bar charts showing mean values for LV functional measures divided by diabetes
status and ethnicity. NT-proBNP (A), E/e9 (B), and peak s9 (C) (age and sex adjusted). P values are
for ethnicity3 glucose tolerance category interactions. D–F: Predicted LV function (95% CI) by HbA1c
in South Asians and Europeans. All values adjusted for age and sex. Log-transformed NT-proBNP
(D), E/e9 (E), and peak s9 (F). P values are for ethnicity 3 HbA1c interactions. DM, diabetes.
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observed in younger than older age
groups; exclusions or restrictions to the
study population, e.g., by disease, risk
factor, or medication status; and the
functional measures used. Few studies
have explored the role of associated
confounders, and many were too small
for detailed analysis.
The greater adverse effect of
hyperglycemia on LV function in South
Asians is in keepingwith our ﬁndings of a
greater effect on CVD events (6). This
may be a consequence of a longer
exposure to hyperglycemia. We show
that diabetes duration is greater in
South Asians, but in the absence of
repeated longitudinal measures of
HbA1c this proposal is speculative.
Certainly, in people with established
diabetes, we show as others do that a
longer diabetes duration is associated
with adverse LV function; this appears
independent of hypertension and CHD
(16). Long-standing hyperglycemia is
associated with multiple adverse effects
including increased oxidative stress,
altered energy metabolism, accelerated
ﬁbrosis, and accumulation of advanced
glycation end products in the
myocardium and aorta (34,35) that may
adversely affect LV function. However,
when we took account of the greater
diabetes duration in South Asians,
acting as a proxy for duration of
exposure, we found that neither it nor
the greater level of hyperglycemia could
account for the more adverse LV
function in this ethnic group. This may
suggest on the one hand that duration
of exposure has little to do with the
greater impact of hyperglycemia on
function in South Asians or,
alternatively, reﬂect the marked
imprecision inherent in estimating
diabetes duration.
NT-proBNP is an acceptedmeasure of LV
global dysfunction (16) that predicts
CVD (36). We are unaware of previous
comparisons of NT-proBNP between
South Asians and Europeans and show
that unadjusted values are elevated in
South Asians. Since NT-proBNP is
produced by the ventricles and LV mass
differs by ethnicity (20), we additionally
adjusted for LV mass (24,37). This
further enhanced the ethnic difference
in NT-proBNP. Conventionally, EF is
often used as a measure of systolic
function; however, the association
between diabetes and EF is inconsistent.
While some report lower EF in patients
with diabetes (38), numerous studies
have found no signiﬁcant adverse effect
of diabetes (39,40), probably because
diminished longitudinal function is
compensated for by an increase in radial
function (41,42). For this reason, we
used tissue Doppler s9 as a more
sensitive index of systolic function that
also predicts future CVD (28). For
diastolic function, E/e9 was used, as
unlike E/A ratio, it is not subject to
pseudonormalization and also predicts
future CVD (43,44). Based on ethnic
differences in the relationship between
HbA1c and s9 and E/e9, respectively, and
previously reported associations
between these measures and future
CVD (28,44,45), a 1% increment in HbA1c
would increase CVD risk in South Asians
by 7–10% more than that observed in
Europeans.
There are several strengths to this study.
The SABRE cohort recruited from
primary care without exclusion. As
registration with primary care is free,
and the gateway to comprehensive
health care, it forms a representative
sampling frame. Previous studies have
either focused on those admitted to
hospital, decisions for which may be
biased by ethnicity, or excluded people
with clinical and subclinical disease, risk
factors, and medication. If we had
excluded such individuals in this study,
only 10.3% of Europeans and 5.5% of
South Asians would have been eligible.
As CVD and risk factors differ by
ethnicity, such exclusion likely biases
the comparison and results in highly
selected, unrepresentative samples,
making it difﬁcult to generalize ﬁndings.
Our measures of LV dysfunction and risk
factors are relatively comprehensive,
enabling detailed exploration of
pathways.
Study Limitations
Our study has several limitations:
sample sizes were relatively small, and
consequently we may have insufﬁcient
power to detect some clinical important
differences. We only studied older-age
survivors; this may have introduced a
survivor bias. However, detectable
subclinical LV disease emerges in older
age (10), and we have shown that
overall survival rates in this cohort are
equivalent by ethnicity (46).While those
who survived and attended clinic were
healthier at baseline compared with
those who did not, these differences
were also similar by ethnicity and are
therefore unlikely to have seriously
biased comparisons (6). Another
limitation is that the majority of South
Asians in this study were ﬁrst-
generation migrants of Punjabi Sikh
origin, and although most South Asian
populations worldwide have an
increased prevalence of both diabetes
and CVD, our ﬁndings may not
necessarily apply to all people of South
Asian ethnicity. Last, the data
presented in this article are based on
cross-sectional analyses made at
follow-up and cannot address issues of
causality.
In conclusion, hyperglycemia may be
more detrimental to global, systolic, and
diastolic LV function in South Asians
Table 3—Ethnic differences (South Asian vs. European) in LV function in
people with known diabetes
Mean ethnic difference (95% CI) P
NT-proBNP (pg/mL)
Unadjusted 59.8 (2.72–116.9) 0.04
Model 1 75.6 (22.4–128.8) 0.006
Model 2 62.0 (5.1–118.9) 0.03
E/e9
Unadjusted 1.92 (0.88–2.96) ,0.0001
Model 1 2.16 (1.15–3.17) ,0.0001
Model 2 1.91 (0.86–2.96) ,0.0001
Peak s9 (cm/s)
Unadjusted 20.41 (20.81 to 20.01) 0.05
Model 1 20.47 (20.87 to 20.07) 0.02
Model 2 20.45 (20.87 to 20.03) 0.04
Model 1, adjusted for age and sex; model 2, adjusted for age, sex, HbA1c, and diabetes duration.
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than Europeans. This does not just apply
to diabetes but occurs across the
glycemic range. Understanding why
South Asians are particularly sensitive to
the effects of hyperglycemia and
associated risk factors, such as
hypertension, dyslipidemia, and
microvascular disease, on LV function
would help elucidate mechanisms and
inform strategies for prevention and
treatment. These may need to be
implemented earlier in the course of
disease in South Asians than Europeans,
or South Asian people may require more
aggressive treatment for a given
cardiometabolic risk factor level. Given
the predicted marked increase in
diabetes prevalence in South Asians
worldwide, further studies on this
question are urgently required.
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